{"id":"h-t-l14","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"T-L14 works by expanding and activating T-cells to target and kill cancer cells. This is achieved through a process that involves the activation of T-cells and the enhancement of their anti-tumor activity.","oneSentence":"T-L14 is a T-cell therapy that enhances anti-tumor immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:32.946Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT04713670","phase":"PHASE4","title":"Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-03-10","conditions":"H. Pylori Infection","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"(H) T-L14","genericName":"(H) T-L14","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"T-L14 is not mentioned in the provided facts, but T-V14 is mentioned as an intervention in a clinical trial for H. Pylori Infection. The clinical trial compares Vonoprazan-based versus Lansoprazole-based triple therapy, high dose dual therapy, bismuth and non-bismuth quadruple therapy in the first-line treatment of Helicobacter Pylori Infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}